Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CO2MO melanoma IOpener-guided pembrolizumab study
NL-OMON59321Phase 4Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pembrolizumab in cutaneous melanoma (CM), sponsored by Leiden University Medical Center. Primary endpoint: 1-year progression-free survival. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON59321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59321.